Manchester, UK-based Concept Life Sciences, an integrated drug discovery, development and analytical services company, has acquired Scottish contract research organisation Aquila BioMedical.
Aquila, a University of Edinburgh spin out, has expertise in preclinical contract research on therapeutics for oncology, biomarker discovery, and target expression, with services covering a wide range of in vitro and in vivo proof-of-concept studies.
According to Concept, the acquisition is “a pivotal addition” to its own services supporting the drug discovery and development process.
“The company’s offering in translational biology adds significant value to our current discovery services, and broadens the wider group’s therapy offering,” noted Concept’s executive chairman Michael Fort.
Financial terms of the deal were not disclosed.
By Selina McKee
Source: Pharma Times
Decades ago, the founder-led biotech was rare and considered the tougher path to follow. Now there is a trend of founder-led biotechs that have risen in prominence in recent years, going from startup to well known with lightning speed. Scientists-turned C-suite occupants know their technology inside out. They’ve got credibility both at the bench working with their research teams and in the boardrooms selling their future products.
Pfizer’s revenue could reach $101.3 billion in 2022, with major contributions coming from the company’s BioNTech-partnered COVID vaccine and an antiviral therapeutic that has shown stellar clinical data, SVB Leerink analyst Geoffrey Porges projected in a Monday note to clients.
In a survey commissioned by GlaxoSmithKline’s consumer health division of 2,000 working people in the U.S., almost 70% admitted to clocking in while sick, often because they couldn’t afford to lose a day’s pay. Black and Latina women were 10% more likely than white women to shun taking sick time for fear of fallout from their boss, according to the company’s 2021 Temperature Check Report.
